<DOC>
	<DOCNO>NCT02739477</DOCNO>
	<brief_summary>This study aim evaluate favipiravir high dose tolerance male survivor Ebola Virus Disease ( EVD ) Ebola Virus ( EBOV ) RNA semen . This dose escalation study 3 cohort 6 patient , dose level include 2 sentinel patient .</brief_summary>
	<brief_title>Tolerance Activity Evaluation High Doses Favipiravir Against Ebola Virus Semen</brief_title>
	<detailed_description>Rational : - Data suggest persistence EBOV semen month end EVD sexual transmission EBOV - Encouraging result favipiravir efficacy reduce mortality EVD JIKI trial ( NCT02329054 ) - Favipiravir trough plasma concentration JIKI trial lower predict population pharmacokinetic model , suggest increase dose might necessary achieve therapeutically relevant exposure . Objectives : - Primary objective : assess clinical biological tolerance high-dosed favipiravir bid 14 day - Secondary objective : ass activity favipiravir evolution EBOV RNA infectious load semen treatment ; trough plasma semen concentration favipiravir ; genetic factor associate favipiravir pharmacokinetic . Dose escalation scheme : Each patient cohort receive favipiravir loading dos 4800 mg Day 1 ( 2400 mg bid ) , follow 3600 mg ( 1800 mg bid ) Day 2 14 ( cohort 1 ) , 3600 , 4200 4800 mg Day 2 14 ( cohort 2 3 ) , depend previous cohort result . Escalation rule base number patient undergoing treatment-related adverse event ( TRAE ) grade 3 4 accord Common Terminology Criteria Adverse Events v4.03 ( CTCAE ) , define investigator sponsor . Participants attend medical visit Day 1 , Day 3 , Day 7 , Day 10 , Day 14 , Day 21 clinical tolerance assess daily phone call Day 1 Day 14 . At end first cohort : - TRAE , cohort 2 give 2400 mg bid Day 2 14 ; - 1 2 TRAE observe , cohort 2 give 2100 mg bid Day 2 Day 14 ; - 3 TRAE observe , cohort 2 give dose cohort 1 . At end cohort 2 , rule apply cohort 3 , without exceed 4800 mg favipiravir per day . Each cohort include 6 patient . Each dose level comprise 2 sentinel patient . In interest , patient include cohort detection EBOV RNA semen RT-PCR ( CT &lt; 38 ) Day 21 , could include next cohort . Recruitment start among PostEbogui cohort coast Guinea .</detailed_description>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>male survivor biologically confirm EVD age &gt; = 18 year EBOV RTPCR semen cycle threshold [ Ct ] &lt; 38 Day 7 semen aliquot available late quantification EBOV sign informed consent Non EBOV RTPCR blood cycle threshold [ Ct ] &lt; 38 Day 7 Biological abnormality high grade 2 accord CTCAE ( v4.03 ) follow parameter : creatinine , ASAT , ALAT , alkaline phosphatase , total bilirubin Fridericia correct QT interval ( QTc ) &gt; 450 m Concomitant use QT/QTc intervalprolonging drug drug could cause electrolyte imbalance , : loop diuretic , thiazide diuretic related Previous gout attack ongoing treatment gout hyperuricemia Ongoing pyrazinamide treatment drug know induce hyperuricemia Previous hypersensitivity reaction due nucleoside analogue Symptom biological value suggest systemic disorder ( renal , hepatic , cardiovascular , pulmonary ) medical condition could interfere result interpretation compromise participant ' health Explicit refusal comply proper use drug ( condom use )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Favipiravir</keyword>
	<keyword>Tolerance</keyword>
	<keyword>Survivor</keyword>
	<keyword>Ebola Virus</keyword>
	<keyword>Genital reservoir</keyword>
	<keyword>Guinea</keyword>
</DOC>